复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究

目的:探讨复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌的临床疗效。方法:按照便利抽样法选取原发性肝癌患者102例作为研究对象,随机分为研究组和对照组各51例,对照组采取肝动脉栓塞化疗术治疗,研究组在对照组的基础上采用复元活血汤合化积丸治疗,治疗时间为6周,进行3年随访。比较两组患者治疗前、治疗后6个月KPS评分、汉密尔顿抑郁量表(HAMD)评分、甲胎蛋白(AFP)水平,以及治疗后3年疾病复发、生存情况、不良反应发生情况。结果:治疗前,研究组的KPS评分、HAMA评分、AFP水平与对照组比较差异均无统计学意义(P>0.05)。治疗后研究组KPS评分高于对照组,HAMA评分、AFP水平低于对照组,均有统计学意义(P<0.05)。肿瘤复发率研究组为13.73%,低于对照组的49.02%;研究组1年生存率、2年生存率、3年生存率分别为88.24%、76.47%、58.82%,高于对照组的66.67%、45.10%、29.41%,均有统计学意义(P<0.05)。不良反应发生率研究组为47.06%,低于对照组的82.35%,均有统计学意义(P<0.05)。结论:复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌,有助于降低患者的抑郁情况和AFP水平,减少肿瘤复发和不良反应,提高患者的生存率。

Fuyuan Huoxue decoction plus Huaji pills and hepatic artery embolization in the treatment of primary liver cancer

Objective:To explore the clinical efficacy of Fuyuan Huoxue decoction plus Huaji pills combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer. Methods:According to the convenience sampling method,102 patients with primary liver cancer were randomly divided into study group (51 cases) and control group (51 cases). Hepatic artery embolization chemotherapy was used. The study group was treated with Fuyuan Huoxue decoction and Huaji pills on the basis of the control group. The treatment time was 6 weeks and followed up for 3 years.KPS scores,Hamilton depression scale (HAMD) scores,alpha-fetoprotein (AFP) levels,and disease recurrence,survival,and adverse events were compared between the two groups before treatment and 6 months after treatment. Results:Before treatment,the KPS score,HAMA score and AFP level of the study group were not significantly different from the control group,and there was no significant difference ( P >0.05).After treatment,the KPS score of the study group was higher than that of the control group,and the HAMA score and AFP level were lower than the control group ( P <0.05).The tumor recurrence rate was 13.73% in the study group,which was lower than the control group of 49.02%.The 1-year survival rate,2-year survival rate,and 3-year survival rate of the study group were 88.24%,76.47%,and 58.82%,respectively,which were higher than the control group's 66.67%,45.10%,and 29.41%,all of which were statistically significant ( P <0.05).The incidence of adverse reactions was 47.06% in the study group,which was lower than that in the control group (82.35%),which was statistically significant ( P <0.05). Conclusion:Fuyuan Huoxue decoction combined with hepatic artery embolization chemotherapy for primary liver cancer has a positive effect ,and also helps patients to better receive treatment and reduce depression and AFP levels. Reducing tumor recurrence and adverse reactions and improving the survival rate of patients can be promoted clinically.